Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance. The PRAX news page on Stock Titan aggregates company announcements, clinical updates, regulatory milestones and capital markets activity related to its precision neuroscience pipeline.
Investors and followers of Praxis can use this page to track developments across the company’s diversified CNS portfolio. News items include progress updates on late-stage product candidates such as ulixacaltamide for essential tremor, vormatrigine for focal onset seizures and generalized epilepsy, relutrigine for developmental and epileptic encephalopathies (DEEs), and elsunersen for early-onset SCN2A-DEE. Praxis frequently reports on Phase 2 and Phase 3 study readouts, FDA interactions such as pre-NDA meetings and Breakthrough Therapy Designations, and changes to registrational trial designs.
The feed also covers corporate and financial disclosures, including underwritten public offerings, at-the-market equity programs, and governance or leadership changes. Form 8-K filings referenced in press releases provide additional detail on clinical data, regulatory feedback and financing terms. Because Praxis emphasizes precision neuroscience and genetic epilepsies, its news often highlights mechanistic data, biomarker findings and functional outcomes in epilepsy and movement disorder studies.
By reviewing this PRAX news stream, readers can follow key catalysts such as NDA preparation, pivotal trial milestones, regulatory designations and capital raises that may influence the company’s trajectory as it advances its CNS portfolio. Bookmark this page to access an organized view of Praxis Precision Medicines’ latest public communications and disclosures.
Praxis Precision Medicines (NASDAQ: PRAX) will present new preclinical and clinical data across its precision epilepsy portfolio at the American Epilepsy Society Annual Meeting, Dec 5–9, 2025 in Atlanta.
Praxis will host a scientific exhibit and booth #217, and deliver multiple poster and late-breaking presentations including full RADIANT results showing vormatrigine seizure reductions, EMBOLD OLE relutrigine data, PAC-DEE preclinical framework updates, antisense oligonucleotide emergency use cases for SCN2A DEE, and DDI and preclinical findings across programs.
Praxis Precision Medicines (NASDAQ: PRAX) announced an expert fireside chat on November 24, 2025 at 1:00 PM EST to discuss a deep dive into clinical data for ulixacaltamide. The event will be hosted by HC Wainwright analyst Doug Tsao and feature UCSF statistician Prof. Chuck McCullough alongside Praxis CEO Marcio Souza. The session focuses on interpretation of ulixacaltamide clinical results and will include an analyst-led discussion; registration is available via the company’s provided link.
Praxis Precision Medicines (Nasdaq: PRAX) announced on November 6, 2025 that its Compensation Committee granted restricted stock unit awards covering 6,876 shares to six new non-executive employees under the 2024 Inducement Plan.
The awards were granted on November 3, 2025 as inducements under Nasdaq Listing Rule 5635(c)(4) and will vest in four equal annual installments, subject to continued employment on each vesting date. The 2024 Inducement Plan is used exclusively for equity awards to individuals who were not previously employees or who return after a bona fide non-employment period.
Praxis Precision Medicines (NASDAQ: PRAX) will attend and present at multiple investor conferences in November 2025, including corporate presentations and a fireside chat.
Scheduled events:
- Truist Securities BioPharma Symposium — Nov 6, 2025 at 10:40am ET, Lotte New York Palace Hotel, New York City.
- HC Wainwright Emerging Ideas on BioPharma — Nov 7, 2025 at 12:30pm ET, fireside chat with analyst Doug Tsao (registration available).
- Guggenheim Securities Healthcare Innovation Conference — Nov 10, 2025 at 9:30am ET, InterContinental Boston; live webcast available.
- Jefferies Global Healthcare Conference — Nov 18, 2025 at 1:30pm GMT, Waldorf Hilton London; live webcast available.
Replays of the third quarter earnings webinar and conference webcasts will be posted on Praxis’ Events and Presentations page for approximately 90 days after each event.
Praxis Precision Medicines (NASDAQ: PRAX) reported positive Phase 3 results for ulixacaltamide in essential tremor (Essential3), with Study 1 showing a 4.3-point mean mADL11 improvement at Week 8 (p<0.0001) and Study 2 showing 55% vs 33% maintained response (p=0.037). A pre-NDA meeting with FDA is scheduled for Q4 2025. Praxis plans an interim EMBOLD analysis for relutrigine in Q4 2025 that could support an NDA in early 2026. Vormatrigine POWER1 recruitment is complete with topline readout expected 1H 2026. Pro forma cash and investments are ~$956M, expected to fund operations into 2028.
Praxis (NASDAQ: PRAX) said it reached alignment with the FDA after a Type B meeting and written advice on the protocol and SAP for relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs). The FDA agreed Praxis’ planned interim analysis of the EMBOLD cohort 2 study, scheduled for Q4 2025, may serve as the basis for an NDA submission in early 2026 if positive. The interim will use ~70% of 16-week study patients and is controlled at a 4% alpha; a negative interim would preserve a final analysis at 1% alpha (n≈80). Prior EMBOLD cohort 1 results showed an ANCOVA p-value of 0.0354 for seizure reduction versus placebo. Praxis also opened enrollment in the registrational EMERALD trial in Q3 2025, with completion expected in H2 2026.
Praxis Precision Medicines (NASDAQ: PRAX) priced an underwritten public offering to raise approximately $525 million gross by issuing 3,025,480 shares of common stock at $157.00 per share and pre-funded warrants to buy up to 318,470 shares at $156.9999 each.
The company granted underwriters a 30-day option to purchase up to 501,592 additional shares. The offering is expected to close on or about October 20, 2025, subject to market conditions and customary closing conditions.
Praxis Precision Medicines (NASDAQ: PRAX) announced a proposed public offering of its common stock and, for certain investors, prefunded warrants to buy common stock. The company said all offered securities will be sold by Praxis and underwriters have a 30-day option to buy additional shares up to 15% of the offering. TD Cowen, Piper Sandler, Guggenheim Securities and Truist Securities are joint book-running managers. The offering is made from a shelf registration that became effective on Dec 23, 2024 and is subject to market and customary closing conditions. Final terms will appear in a prospectus supplement; the release is not an offer to sell securities.
Praxis Precision Medicines (NASDAQ: PRAX) reported positive topline Phase 3 results for ulixacaltamide in the Essential3 program for essential tremor (ET) on October 16, 2025. In Study 1 (parallel-group) ulixacaltamide produced a mean Modified Activities of Daily Living-11 improvement of 4.3 points at Week 8 (p<0.0001) and all key secondaries were statistically significant (p<0.001). Study 2 (randomized-withdrawal) met its primary endpoint (maintenance of effect, p=0.0369) and a key secondary (rate of improvement, p=0.0042). The drug was generally well tolerated with no drug-related serious adverse events. Praxis has requested a pre-NDA meeting with the FDA and will host an investor call on October 16, 2025.
Praxis Precision Medicines (Nasdaq: PRAX) announced on October 1, 2025 that its Compensation Committee granted restricted stock unit awards covering an aggregate of 4,200 shares to three new non‑executive employees under the 2024 Inducement Plan.
The awards were granted as inducements material to the employees entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units will vest in four equal annual installments, subject to the recipients' continued employment on each vesting date. The 2024 Inducement Plan is reserved exclusively for equity awards to newly hired individuals or those returning after a bona fide break in service.